Skip to main content
. 2021 Aug 17;110:216–222. doi: 10.1016/j.procbio.2021.08.015

Table 3.

Lipinski’s rule of five for ADME analysis of our inhibitors (ligands).

No. Name Lipinski’s Rule of Five
Drug-likeness
Molecular weight (g/mol) Lipophilicity
(MLogP)
Hydrogen bond donors Hydrogen bond acceptors No. of Rule Violations
Less than 500 Da Less than 5 Less than 5 Less than 10 Less than 2 violations Lipinski’s rule follow
13. Allicin 162 1.18 0 1 0 Yes
11. Benzapril 424 2.23 2 6 0 Yes
10. Captopril 217 0.45 1 3 0 Yes
6. Cilizapril 417 1.79 2 7 0 Yes
8. Enalapril 376 1.32 2 6 0 Yes
2. Fosinopril 563 3.74 1 7 0 Yes
5. Lisinopril 405 −1.46 4 7 0 Yes
3. Moexipril 498 1.54 2 8 0 Yes
12. Perindopril 368 1.36 2 6 0 Yes
4. Quinapril 438 2.17 2 6 0 Yes
9. Ramipril 416 1.98 2 6 0 Yes
1. Teprotide 1101 −3.11 10 13 3: MW > 500,
NH or OH > 5, N or O > 10, 1: MW > 500
No
7. Trandolapril 430 2.19 2 6 0 Yes